Oxford Biomedica.

-to KDC:
-only to happy to stick to discussing the share
-you are, ofcourse, entitled to whatever view you like regarding OXB and Prelude
-i was, in the main, referring to your lengthy post no.12 which does'nt appear to me to do anything regarding the debate for/against OXB but clog the thread up.
-i've no wish to get into any debate other than on OXB
-so, let's ,as you say, stick to discussing OXB

-with the prospect of some decent news-flow regarding their various trials due in the next couple of quarters, if feel the outlook for OXB is reasonable.
-they are well-funded and have a good research pipe-line
-and whilst no expert on the subject, the chart does look quite promising to my eyes.
-it's high risk, but potentially high reward